| 词条 | Lesinurad/allopurinol |
| 释义 |
| drug_name = | type = combo | component1 = Lesinurad | class1 = urate transporter inhibitor | component2 = Allopurinol | class2 = xanthine oxidase inhibitor | pronounce = | tradename = Duzallo | Drugs.com = {{Drugs.com|parent|duzallo}} | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_UN = | legal_NZ = | legal_status = | routes_of_administration = By mouth | CAS_number = | ATCvet = | ATC_prefix = M04 | ATC_suffix = AA51 | PubChem = | DrugBank = | KEGG = D11175 }}Lesinurad/allopurinol (trade name Duzallo) is a fixed-dose combination drug for the treatment of gout. It contains 200 mg of lesinurad and 300 mg of allopurinol. In August 2017, the US Food and Drug Administration approved it for the treatment of hyperuricemia associated with gout in patients for whom target serum uric acid levels have not been achieved with allopurinol alone.[1] References1. ^{{Cite web | url = http://www.medscape.com/viewarticle/884534 | title = FDA Clears First Fixed-Dose Combination Treatment for Gout | date = August 21, 2017 | publisher = Medscape}} {{musculoskeletal-drug-stub}} 2 : Antigout agents|Combination drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。